Skip to content

Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients

Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01780467
Enrollment
40
Registered
2013-01-31
Start date
2013-03-31
Completion date
2015-12-31
Last updated
2013-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Loss aversion, Dopamine, Parkinson's disease

Brief summary

Use lay language. Many decisions involve the possibility of gaining or losing relative to the status quo. The loss aversion behaviour is a cognitive concept explaining that people are more sensitive to the possibility of losing objects or money than they are to the possibility of gaining the same objects or amounts of money. We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money. The second purpose is to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control. 2 groups : * 20 parkinsonian patients (tested two times : with and without treatment by L dopa) * 20 healthy paired control Description of the protocol for patients : J0 : Inclusion visit (duration : 4h): * motor assessment (UPDRS) * neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin scale, UPPS, MADRS, Hamilton, LARS). J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or without treatment) : Each acquisition was composed by an orientation sequence+ an anatomic sequence + a functional sequence. For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the MRI acquisitions.

Detailed description

Use lay language. Many decisions involve the possibility of gaining or losing relative to the status quo. The loss aversion behaviour is a cognitive concept explaining that people are more sensitive to the possibility of losing objects or money than they are to the possibility of gaining the same objects or amounts of money. We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money. The second purpose is to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control. 2 groups : * 20 parkinsonian patients (tested two times : with and without treatment by L dopa) * 20 healthy paired control Description of the protocol for patients : J0 : Inclusion visit (duration : 4h): * motor assessment (UPDRS) * neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin scale, UPPS, MADRS, Hamilton, LARS). J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or without treatment) : Each acquisition was composed by an orientation sequence+ an anatomic sequence + a functional sequence. For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the MRI acquisitions.

Interventions

BEHAVIORALRole of dopamine

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients : * Men or women aged between 35 -75 years * Patients with an idiopathic Parkinson's disease according to UKPDSBB criterias with a disease evolution duration : 5-10 years) * With fluctuations in end of doses + morning akinesia. * Non dement (MMS\>24 ; Mattis \> 130) * Affiliated to National Health system * Having given their informed consent Healthy controls * Men or women aged between 35 to 75 years * Non dement (MMS\>24 ) * Affiliated to National Health system * Having given their informed consent

Exclusion criteria

* Patients : * Patients suffering of an atypical Parkinson syndrome * Psychiatric pathology * Tremor form (≥ 3 (item tremor of UPDRS)) * Patients with Impulsive control disorders * Depression, dementia * Pregnant * Under guardianship * In excluding period for another study * Any contra-indication to MRI Healthy subject * Subject with neurological, psychiatric diseases * Depression, dementia * Pregnant * Under guardianship * In excluding period for another study * Any contra-indication to MRI

Design outcomes

Primary

MeasureTime frame
percentage of signal modificationFrom day 1 (without L Dopa) to day 2 (with L Dopa)

Secondary

MeasureTime frame
Cluster activation sizefrom day 1 (without L Dopa) to day 2 (with LDopa)
Brain activity indicatorsfrom day 1 (without L Dopa) to day 2 (with L Dopa)

Countries

France

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026